Asunto(s)
Antiarrítmicos/efectos adversos , Arritmias Cardíacas/terapia , Desfibriladores Implantables , Campos Electromagnéticos/efectos adversos , Exposición a Riesgos Ambientales/efectos adversos , Marcapaso Artificial , Cardioversión Eléctrica , Electrofisiología , Humanos , Imagen por Resonancia Magnética , Miocardio/metabolismo , TeléfonoRESUMEN
Amiodarone has become an important drug for the treatment of supraventricular and ventricular arrhythmias, in short-term inpatient and outpatient settings. It may also have a role in affecting outcome in patients at high risk for arrhythmic events and sudden death; its place among available therapies is being established in clinical trials.
Asunto(s)
Amiodarona/uso terapéutico , Antiarrítmicos/uso terapéutico , Administración Oral , Amiodarona/administración & dosificación , Amiodarona/efectos adversos , Antiarrítmicos/administración & dosificación , Antiarrítmicos/efectos adversos , Arritmias Cardíacas/tratamiento farmacológico , Interacciones Farmacológicas , Humanos , Infusiones Intravenosas , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
OBJECTIVE: The purpose of this study was to determine the safety of intra-amniotic digoxin injection before late second-trimester pregnancy termination by dilation and evacuation through an assessment of maternal systemic digoxin absorption, cardiac rhythm, and coagulation parameters. STUDY DESIGN: Pregnant women at between 19 and 23 weeks' gestation received 1.0 mg digoxin through intra-amniotic injection and then had serum digoxin levels determined for 48 hours and Holter cardiac monitoring performed for 24 hours. Clotting parameters were assessed before digoxin injection and 24 hours later, at the time of the dilation and evacuation procedure. RESULTS: Eight patients completed the study. The mean (+/-SD) serum digoxin peak concentration was 0.81 +/- 0.22 microg/L (range, 0.5-1.1 microg/L). The mean (+/-SD) time to peak digoxin concentration was 11.0 +/- 5.55 hours (range, 4-20 hours). Ambulatory cardiac monitoring showed no rhythm or conduction abnormalities associated with digoxin. Prothrombin time, partial thromboplastin time, and fibrinogen levels did not change significantly between determinations before and after the dilation and evacuation procedure (11.5 to 11.4 seconds, 24.1 to 24.4 seconds, and 441 to 475 mg/dL, respectively). CONCLUSION: The maximum digoxin concentration peak achieved after intra-amniotic injection was in the low therapeutic range. No rhythm or conduction abnormalities associated with digoxin were noted by Holter monitoring. Coagulation parameters did not change significantly. On the basis of the limited systemic absorption and the absence of clinically significant cardiac or clotting effects, intra-amniotically administered digoxin may be considered safe for use before late second-trimester pregnancy terminations.
Asunto(s)
Aborto Inducido , Digoxina/administración & dosificación , Digoxina/efectos adversos , Digoxina/farmacocinética , Dilatación y Legrado Uterino , Femenino , Fibrinógeno/análisis , Humanos , Tiempo de Tromboplastina Parcial , Embarazo , Segundo Trimestre del Embarazo , Tiempo de ProtrombinaRESUMEN
Historically, risk stratification for survivors of acute myocardial infarction (AMI) has centered on 3 principles: assessment of left ventricular function, detection of residual myocardial ischemia, and estimation of the risk for sudden cardiac death. Although these factors still have important prognostic implications for these patients, our ability to predict adverse cardiac events has significantly improved over the last several years. Recent studies have identified powerful predictors of adverse cardiac events available from the patient history, physical examination, initial electrocardiogram, and blood testing early in the evaluation of patients with AMI. Numerous studies performed in patients receiving early reperfusion therapy with either thrombolysis or primary angioplasty have emphasized the importance of a patent infarct related artery for long-term survival. The predictive value of a variety of noninvasive and invasive tests to predict myocardial electrical instability have been under active investigation in patients receiving early reperfusion therapy. The current understanding of the clinically important predictors of clinical outcomes in survivors of AMI is reviewed in this article.
Asunto(s)
Infarto del Miocardio/diagnóstico , Reperfusión Miocárdica , Muerte Súbita Cardíaca , Electrocardiografía , Femenino , Hemodinámica , Humanos , Masculino , Infarto del Miocardio/complicaciones , Infarto del Miocardio/mortalidad , Infarto del Miocardio/fisiopatología , Infarto del Miocardio/terapia , Pronóstico , Medición de Riesgo , Factores de RiesgoRESUMEN
Concise and complete guidelines of indications for permanent pacemakers are critical for the clinician involved in permanent pacing. A critical appraisal of the American College of Cardiology/American Heart Association 1998 guidelines on indications for permanent pacing clarifies inconsistencies and expands on information within the current guidelines.
Asunto(s)
Estimulación Cardíaca Artificial/normas , Guías de Práctica Clínica como Asunto , Bloqueo Cardíaco/terapia , Humanos , Infarto del Miocardio/terapia , Sociedades Médicas , Síncope/terapia , Estados UnidosRESUMEN
Atrial fibrillation is an extremely common arrhythmia that is associated with significant sequelae. Certain aspects of therapy, such as anticoagulation, are studied in well-constructed randomized trials. Other therapy, such as the maintenance of sinus rhythm with antiarrhythmic agents, is supported by limited evidence. This article reviews the epidemiology and medical treatment of this arrhythmia, addressing anticoagulation, ventricular rate control, and restoration and maintenance of sinus rhythm. Randomized trials in progress that attempt to answer important questions in the management of atrial fibrillation are also discussed.
Asunto(s)
Fibrilación Atrial/tratamiento farmacológico , Antiarrítmicos/uso terapéutico , Anticoagulantes/uso terapéutico , Fibrilación Atrial/complicaciones , Fibrilación Atrial/mortalidad , Fibrilación Atrial/fisiopatología , Trastornos Cerebrovasculares/etiología , Trastornos Cerebrovasculares/prevención & control , Ensayos Clínicos como Asunto , Cardioversión Eléctrica , Sistema de Conducción Cardíaco/fisiopatología , Hemodinámica , Humanos , Morbilidad , Warfarina/uso terapéuticoAsunto(s)
Cardiomiopatía Hipertrófica/terapia , Antagonistas Adrenérgicos beta/administración & dosificación , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Estimulación Cardíaca Artificial/métodos , Femenino , Ventrículos Cardíacos/cirugía , Humanos , Marcapaso Artificial , Propranolol/administración & dosificación , Propranolol/uso terapéuticoAsunto(s)
Enfermedades Cardiovasculares/terapia , Guías de Práctica Clínica como Asunto , Calidad de la Atención de Salud , Derivación y Consulta , Cardiología , Certificación , Medicina Familiar y Comunitaria , Guías como Asunto , Humanos , Mala Praxis/legislación & jurisprudencia , Evaluación de Resultado en la Atención de Salud , Rol del Médico , Estados UnidosRESUMEN
Studies of both the acute and chronic effects of permanent cardiac pacing in patients with dilated cardiomyopathy have produced contradictory results. Similarly, theoretically promising novel pacing techniques such as multisite, His bundle, and right ventricular outflow tract pacing have also yielded mixed results in preliminary studies. In general, at the present time, pacing therapy should be considered investigational for patients with dilated cardiomyopathy who do not have traditional bradycardia indications; nevertheless, pacing therapy may be useful in a small population of patients with dilated cardiomyopathy who have inappropriate timing of left ventricular and left atrial contraction. The beneficial effects of cardiac pacing in some patients with DCM cannot be dismissed out of hand; they must be explained. What is needed is clarification of the best methods to measure any benefits of this therapy: among the options are echocardiographically determined parameters of forward flow and AV valve function, exercise test parameters such as duration and O2 consumption, global and regional ejection fraction, functional classification, quality of life questionnaires, neurohumoral parameters such as plasma atrial natriuretic peptide and catecholamines, and, finally, disease progression and survival.
Asunto(s)
Estimulación Cardíaca Artificial , Cardiomiopatía Dilatada/terapia , Gasto Cardíaco , Estimulación Cardíaca Artificial/métodos , Cardiomiopatía Dilatada/fisiopatología , Hemodinámica , Humanos , Resultado del TratamientoRESUMEN
The primary goals in treatment of unstable angina are to relieve pain and prevent or limit myocardial infarction or ischemia. Patients with distinct, rapid progression of their usual angina pattern should be admitted to a coronary care unit and given heparin and intravenous nitrates as well as aspirin. Cardioselective beta blockers should also be administered when there are no contraindications. Intravenous thrombolytic agents are indicated in patients with objective evidence of ischemia who fit criteria for this therapy. However, thrombolysis is not advocated for routine treatment of unstable angina. Percutaneous transluminal coronary angioplasty or coronary artery bypass grafting should be considered--depending on the location, age, and morphology of the culprit lesion and the degree of left ventricular dysfunction--in patients who have refractory or recurrent ischemia despite aggressive medical therapy. However, in general, high-technology interventions are not a substitute for long-term regimens, such as risk-factor and lifestyle modification, daily aspirin, and pharmacologic therapies aimed at maximizing cardiac function.
Asunto(s)
Angina Inestable/terapia , Angina Inestable/diagnóstico , Angina Inestable/etiología , Angina Inestable/fisiopatología , Angioplastia Coronaria con Balón , Fármacos Cardiovasculares/uso terapéutico , Enfermedad Coronaria/etiología , Enfermedad Coronaria/fisiopatología , HumanosRESUMEN
Atrial fibrillation is a common arrhythmia that frequently results in significant and sometimes refractory clinical symptoms of palpitations, effort intolerance, and breathlessness. The clinical picture, as well as a real risk of embolism, make appropriate management an important priority in medical practice. Older strategies, such as reliance on pharmacologic therapy to control ventricular rate, are being displaced by newer techniques to maintain sinus rhythm. These techniques often involve a combination of electrical cardioversion, use of newer direct-acting AV nodal blocking drugs and antiarrhythmic medication, AV node ablation and modification procedures, and permanent pacemaker therapy. These newer treatment approaches--together with anticoagulation and antiplatelet therapy--continue to evolve, with the goal of optimizing the lifespan and lifestyle of patients with this rhythm disorder.
Asunto(s)
Fibrilación Atrial/terapia , Anciano , Anticoagulantes/uso terapéutico , Fibrilación Atrial/fisiopatología , Ablación por Catéter , Cardioversión Eléctrica , Electrocardiografía , Ventrículos Cardíacos/fisiopatología , Humanos , Persona de Mediana EdadAsunto(s)
Arritmias Cardíacas/diagnóstico , Estimulación Cardíaca Artificial , Cardiología/educación , Educación Médica , Electrofisiología/educación , Especialización , Adulto , Arritmias Cardíacas/terapia , Curriculum , Desfibriladores Implantables , Evaluación Educacional , Humanos , Marcapaso Artificial , Estados UnidosRESUMEN
BACKGROUND: Mortality from acute myocardial infarction is substantially less than it was two and even one decade ago. This improvement in both short-term and postdischarge outcome results both from early interventions to restore myocardial perfusion and mitigate expansion and remodeling, and from later assessment and management of functional status at the time of hospital discharge. OBJECTIVE: Recent studies suggest that invasive evaluation of the patient who has had a myocardial infarction (MI) should not be recommended on a routine basis. This review provides an approach to the noninvasive assessment of the patient. DISCUSSION: Stress testing to ascertain post-MI ischemia, ejection fraction determination to evaluate ventricular volumes and function, and ambulatory electrocardiographic monitoring, electrophysiologic study, and signal-averaged electrocardiography to assess presence and type of ventricular ectopy are discussed. CONCLUSION: The approach to the post-MI patient offered herein is felt to be medically sound and cost-effective. Refinement and alterations in this approach will be necessary as outcomes in specific patient groups, such as thrombolysis patients, women, and the elderly, become clearer.